2022
Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer.
Ang C, Low Q, Ho C, Walsh R, Asokumaran Y, Choo J, Chan G, Ho J, Ang Y, Tan L, Yong W, Sundar R, Chee C. Real-world experience on the efficacy and tolerability of biweekly trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer. Journal Of Clinical Oncology 2022, 40: 3584-3584. DOI: 10.1200/jco.2022.40.16_suppl.3584.Peer-Reviewed Original ResearchMetastatic colorectal cancerTAS-102Median PFSBiweekly dosesDiscontinued treatment due to toxicityColorectal cancerDose of TAS-102Treated with TAS-102Treatment due to toxicityMetastatic colorectal cancer patientsGrade 3 neutropeniaThird-line treatmentInitiation of treatmentRetrospective observational studyBiweekly regimenDose delaysFebrile neutropeniaHigher neutropeniaStandard regimenDose reductionBevacizumabGrade 3Adverse eventsDisease progressionNeutropeniaPhase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
Lee M, Wong A, Ow S, Sundar R, Tan D, Soo R, Chee C, Lim J, Yong W, Lim S, Goh B, Wang L, Lee S. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors. Targeted Oncology 2022, 17: 141-151. PMID: 35195837, PMCID: PMC8995271, DOI: 10.1007/s11523-022-00867-0.Peer-Reviewed Original ResearchConceptsHER2+ metastatic breast cancerDose-limiting toxicityMetastatic breast cancerBreast cancerSubcutaneous trastuzumabSolid tumorsConclusionsThe recommended phase II dosePharmacokinetic analysisRecommended phase II doseHER2+ breast cancerAdvanced solid tumorsPalliative systemic therapyMetastatic solid tumorsResultsThirty-seven patientsArea under the curveWeekly paclitaxelNeoadjuvant therapyStable diseaseFebrile neutropeniaPartial responseSystemic therapyMethodsEligible patientsEfficacy signalsElectrolyte disturbancesBiliary tractCiprofloxacin plus gemcitabine-based chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma: A pilot study of microbiome manipulation.
Cheo S, Lee J, Walsh R, Sundar R, Choo J, Chan G, Yong W, Meah W, Khor C, Chee C. Ciprofloxacin plus gemcitabine-based chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma: A pilot study of microbiome manipulation. Journal Of Clinical Oncology 2022, 40: 570-570. DOI: 10.1200/jco.2022.40.4_suppl.570.Peer-Reviewed Original ResearchMetastatic pancreatic ductal adenocarcinomaGemcitabine-based chemotherapyProgression free survivalPancreatic ductal adenocarcinomaResistance to chemotherapyProgressive diseaseOverall survivalDuctal adenocarcinomaTreated with nab-paclitaxelMedian progression free survivalPancreatic ductal adenocarcinoma tumor microenvironmentGrade 1/2 rashSafety of ciprofloxacinResistance to gemcitabinePost-treatment stool samplesMicrobiome changesNab-paclitaxelOral ciprofloxacinFebrile neutropeniaFree survivalMedian agePrimary endpointSecondary endpointsTumor microenvironmentGut microbiome changes
2018
Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases.
Chan D, Syn N, Neogh C, Phua N, . E, Ho J, Sundar R, Tan C, Ngoi N, Chee C, Shabbir A, So J, Yong W. Extended outcomes of intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastases. Journal Of Clinical Oncology 2018, 36: 125-125. DOI: 10.1200/jco.2018.36.4_suppl.125.Peer-Reviewed Original ResearchConversion gastrectomyPeritoneal metastasisGastric cancerIP paclitaxelMedian OSPeritoneal cytologyDay 1Positive peritoneal washing cytologyTreated with 8 cyclesSurvival rateNegative peritoneal cytologyPeritoneal washing cytologyRecurrent gastric adenocarcinomaHand-foot syndromeMedian follow-upOverall survival rateWeek of restTime of reportingMedian no.Tumor perforationSystemic chemotherapyFebrile neutropeniaIncreasing drug concentrationPeritoneal diseasePeritoneal dissemination